Historically, the high toxicities of allogeneic hematopoietic cell transplantation (HCT) precluded this therapy in older adults. However, with more tolerable regimens, better donor selection and better supportive care, allogeneic transplant has moved quickly to patients ⩾ 60 years, which actually represents the area of greatest growth. 1 Many studies have shown reasonable outcomes after allogeneic HCT indicating older age alone is not a barrier to HCT. 2, 3 It still remains true very few transplants are offered to patients 475 years of age and that in most large series, older age, among those medically cleared to undergo HCT, is still associated with higher risks of non-relapse death after both autologous and allogeneic HCT. 4, 5 For diseases such as AML, the poor prognosis in older adults after standard therapy forces the question of whether to pursue allogeneic HCT. 6, 7 Unfortunately, we lack well-designed studies documenting the risks and benefits of transplant versus nontransplant strategies. In the Fellowship of the Ring from the Lord of the Rings Stories by JRR Tolkien, Gandalf famously says '…All we have to decide is what to do with the time that is given us.' Patients diagnosed with most hematologic malignancies face these same issues of fatalism with a life-limiting disease. The question about what to do with the remaining time rings true for older adults considering the transplant. Should one pursue therapy for curative intent and potentially sacrifice their quantity or quality of life? In looking at patient preferences for treatment, weighing quantity versus quality of life, an understanding of the decision-making process is important.
In this context, the overview of decision-making in older adults for HCT by Randall et al. 8 is a welcome addition to the literature and calls attention to an unmet need. The authors provide a framework for decision-making, and compare and contrast decision-making for younger patients and older patients, generally focusing on allogeneic HCT. They underscore differences in domains that may influence decision-making in these age groups and suggest ways to help older adults through the process and hopefully to a treatment decision aligned with their personal preferences and values. This also raises the question of whether our present transplant-care teams are equipped to address issues of aging to properly counsel patients on matters such as functional impairment, multi-morbidity, cognitive impairment, and caregiver burden or distress given that older transplant patients have a surprisingly high prevalence of health vulnerabilities. 9 For example, most centers have a process in place to address fertility preservation in young patients, but lack a similar approach to evaluate or manage cognitive impairment or falls. Although the review considers allogeneic HCT, ironically the lower treatment-related mortality of autologous HCT allows even older and more frail patients to be evaluated for autografting.
It is essential to understand that there is marked heterogeneity in the aging process-that a person's chronologic age may not necessarily be their physiologic age due to geriatric principles such as comorbidity and physical function. In the current practice, patients submitted for transplant are medically cleared based on a Gestalt-like assessment of performance status. However, we know that comorbidity, functional status and standard geriatric measures will stratify outcomes for older transplant patients. 10, 11 Likewise, psychosocial health not only plays an important role as a prognostic factor, but psychosocial changes after transplant also influence post-transplant quality of life. Prospective studies are needed though, as morbidity and mortality classified as transplant-related may also be a consequence of pre-existing health conditions, especially for older adults being followed for 2-5 years after HCT.
We require research into better tools to characterize the heterogeneous nature of aging to more accurately estimate outcomes in the short and long term following HCT and non-HCT approaches. Yet, uncertainty will always exist. Therefore, some of the authors' suggestions about improving process could be implemented now. Specifically, starting the transplant discussion earlier in the disease process with the transplant team and enhancing or incorporating geriatrics expertise training in the transplant team have low risks and large potential gains. The science of decision-making suggests that advancing age is associated with greater risk aversion, further supporting a different or more prolonged decision-making process for HCT. 12, 13 Transplant centers and the transplant community must adapt to the growing population of older adults being considered for HCT. Improving the decision-making process should ensure older adults decide on HCT based on the best data available and aligned with their personal values.
